查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1908606

乳癌诊断市场规模、份额和趋势分析报告：按类型、产品、应用、最终用途、地区和细分市场预测（2026-2033 年）

Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Product (Platform-based, Instrument-based), By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

乳癌诊断市场概览

全球乳癌诊断市场预计到 2025 年价值 58.6 亿美元，预计到 2033 年将达到 113.6 亿美元。

预计从 2026 年到 2033 年，其复合年增长率将达到 8.8%。这一增长可归因于癌症发生率的上升以及政府为提高筛检和诊断率而加强的力度。

乳癌发生率的上升预计将推动乳癌诊断市场的发展。根据美国癌症协会（ACS）发布的《2024年乳癌事实与数据》，乳癌仍然是美国女性最常见的癌症。预计2024年将新增310,720例侵袭性乳癌病例和55,720例乳管原位癌（DCIS）病例。

多种因素导致乳癌发生率上升，包括年龄增长、生活方式改变、遗传易感性和环境因素。随着预期寿命的延长，越来越多的女性进入乳癌高风险年龄层。此外，肥胖、缺乏运动、荷尔蒙疗法乳癌乳癌的需求。虽然乳房X光摄影仍然是乳癌筛检的黄金标准，但数位乳房断层合成（DBT）、造影乳房X光乳房X光摄影、超音波、磁振造影（MRI）和分子诊断检测技术的进步推动了市场成长。人工智慧（AI）在影像学中的应用进一步提高了早期检测能力，提高了准确性，并减少了假阳性和假阴性结果。此外，液态生物检体和基于生物标记的诊断方法已成为检测乳癌和监测治疗效果的非侵入性工具。

为了应对日益严重的乳癌负担，全球医疗卫生系统加大了对乳癌筛检计画的投入。各国政府和私人医疗机构扩大了诊断服务的覆盖范围，尤其是在筛检率历来较低的发展中地区。对早期检测和个人化医疗的重视加速了新一代定序（NGS）、基因检测和伴随诊断技术的普及应用。随着乳癌发病率的持续上升，乳癌诊断市场也经历了持续成长。技术的不断进步，加上公众意识的提高和筛检服务的普及，推动了对能够实现更早期、更精准癌症检测的创新诊断解决方案的需求。

扩大乳癌筛检的报销范围和保险覆盖率预计将推动市场成长。世界各地的政府机构，例如德国联邦联合委员会，已核准该检测纳入全国报销范围。在美国，医疗补助计划 (Medicaid)、医疗保险计划 (Medicare) 和第三方支付机构的福利计划涵盖乳癌基因检测的费用，包括 BRCA1 和 BRCA2 基因检测，而且全球范围内进行的检测数量正在增加。此外，医疗保险 B 部分 (Medicare Part B) 为 40 岁及以上的女性报销每年一次乳房 X 光检查数位乳房摄影检查 80% 的费用。

此外，Agendia于2025年2月宣布，布鲁塞尔国家疾病与意外保险研究所（INAMI-RIZIV）已扩大MammaPrint的承保范围，将其用于新辅助化疗。自2025年1月1日起，这意味着HR+/HER2阴性早期乳癌患者将获得全额报销，并可透过核心针穿刺活检进行基因组检测，以指南新辅助治疗方案的发展。此次承保范围的扩大标誌着在为患者提供更个人化的治疗方面迈出了重要一步。布鲁塞尔自由大学肿瘤学荣誉教授Martine Picart教授就此进展的影响评论道：「MammaPrint在比利时应用于核心针穿刺活检样本是乳癌个性化治疗的一个重要里程碑。新辅助化疗的益处巨大，而MammaPrint尤其能够帮助医生更精准地制定治疗方案，如果选择合适的治疗方案，则有可能小规模手术次数。」

目录

第一章调查方法和范围

第二章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关及附随市场展望
  • 市场趋势与展望
  • 市场动态
  • 商业环境分析
    • PESTLE分析
    • 波特五力分析
  • 新冠疫情影响分析

第四章 按类型进行业务分析

  • 乳癌诊断市场：类型差异分析，2025 年和 2033 年
  • 影像
  • 切片检查
  • 基因组检测
  • 血液检查
  • 其他的

第五章：依产品进行业务分析

  • 乳癌诊断市场：产品差异分析（2025 年和 2033 年）
  • 基于平台的产品
  • 设备类产品

第六章：按应用程式进行业务分析

  • 乳癌诊断市场：应用趋势分析（2025 年和 2033 年）
  • 筛检
  • 诊断与预测
  • 预后诊断
  • 研究

第七章 依最终用途进行业务分析

  • 乳癌诊断市场：按最终用途分類的变化分析（2025 年和 2033 年）
  • 医院和诊所
  • 医学检查室/诊断中心
  • 其他的

第八章：区域商业分析

  • 区域市场概览
  • 北美洲
    • 2021-2033年北美乳癌诊断市场
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2021-2033年欧洲乳癌诊断市场
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2021-2033年亚太地区乳癌诊断市场
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2021-2033年拉丁美洲乳癌诊断市场
    • 主要国家的趋势
    • 法律规范
    • 竞争场景
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2021-2033年中东及非洲乳癌诊断市场
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争情势

  • 公司分类
  • 策略规划
    • 获得
    • 合伙
    • 新平台推出
    • 其他的
  • 公司简介/上市资讯
    • Hologic Inc.
    • Genomic Health（Exact Sciences Corporation）
    • BD
    • Danaher
    • Koninklijke Philips NV
    • QIAGEN
    • Thermo Fisher Scientific Inc
    • Myriad Genetics
    • Argon Medical Devices, Inc.
    • F. Hoffmann-La Roche Ltd.
Product Code: GVR-3-68038-694-3

Breast Cancer Diagnostics Market Summary

The global breast cancer diagnostics market size was estimated at USD 5.86 billion in 2025, and is projected to reach USD 11.36 billion by 2033, growing at a CAGR of 8.8% from 2026 to 2033. The growth can be attributed to the increasing prevalence of cancer and rising government initiatives to increase the screening and diagnostic rates.

The increasing incidence of breast cancer is expected to drive the breast cancer diagnostics market. According to the American Cancer Society's Breast Cancer Facts & Figures 2024, breast cancer remained the most commonly diagnosed cancer among women in the U.S. In 2024, an estimated 310,720 new cases of invasive breast cancer were expected to be diagnosed, along with 55,720 cases of ductal carcinoma in situ (DCIS).

Several factors contributed to the increasing incidence of breast cancer, including aging populations, lifestyle changes, genetic predisposition, and environmental influences. As life expectancy increased, more women reached ages where breast cancer risk was higher. In addition, risk factors such as obesity, sedentary lifestyles, hormonal therapies, and delayed childbearing were linked to a greater likelihood of developing breast cancer. Increased awareness and improved screening programs also led to a rise in reported cases, as more cancers were detected at earlier stages. With the growing number of breast cancer cases, the need for effective and accurate diagnostic technologies. Mammography remained the gold standard for breast cancer screening, but advancements in digital breast tomosynthesis (DBT), contrast-enhanced mammography, ultrasound, MRI, and molecular diagnostic tests drove market growth. The integration of AI in imaging interpretation further improved early detection capabilities, enhancing accuracy while reducing false positives and negatives. In addition, liquid biopsy and biomarker-based diagnostics emerged as non-invasive tools for detecting breast cancer and monitoring treatment response.

Healthcare systems worldwide have increased investments in breast cancer screening programs to address the rising burden. Governments and private healthcare providers expanded access to diagnostic services, particularly in developing regions where screening rates had historically been lower. The focus on early detection and personalized medicine accelerated the adoption of next-generation sequencing (NGS), genetic testing, and companion diagnostics. As breast cancer incidence continued to rise, the breast cancer diagnostics market experienced sustained growth. Ongoing advancements in technology, combined with greater awareness and improved accessibility to screening, drove demand for innovative diagnostic solutions that enabled earlier and more accurate cancer detection.

The increasing reimbursement and insurance coverage for breast cancer testing is anticipated to drive market growth. Government agencies in various countries, such as the German Federal Joint Committee, have approved tests for nationwide reimbursement. In the U.S., Medicaid, Medicare, and third-party payer benefit plans cover the cost of breast cancer genetic testing, including BRCA1 and BRCA2 tests, increasing the number of procedures conducted globally. Furthermore, Medicare Part B covers 80% of the cost of one mammogram and digital mammogram screening per year for women aged 40 and older.

Moreover, In February 2025, Agendia, Inc. announced that the National Institute for Sickness and Invalidity Insurance (INAMI-RIZIV) in Brussels has expanded the reimbursement criteria for MammaPrint, now covering its use in the neoadjuvant setting. Effective January 1, 2025, this decision allows full reimbursement for patients with HR+/HER2-negative early-stage breast cancer, enabling genomic testing on core needle biopsies to guide neoadjuvant treatment decisions. This expansion marks a significant step forward in providing patients with more personalized care. Professor Martine Piccart, Honorary Professor of Oncology at the Universite Libre de Bruxelles, highlighted the impact of this advancement, stating, "The ability to use MammaPrint on core needle biopsy specimens in Belgium represents a major milestone for personalized breast cancer treatment. The benefits of neoadjuvant therapy are substantial, especially when guided by MammaPrint, as it enables physicians to tailor treatment plans more precisely. This can lead to less extensive surgical procedures when the appropriate treatment is selected."

Global Breast Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For this report, Grand View Research has segmented the breast cancer diagnostics market by type, product, application end use, and region.

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Imaging
  • Biopsy
  • Genomic Tests
  • Blood Tests
  • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Platform-based products
    • Next Generation Sequencing
    • Microarrays
    • PCR
    • Others
  • Instrument-based products
    • Imaging
    • Biopsy
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Screening
  • Diagnostic & Predictive
  • Prognostic
  • Research
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Medical labs & Diagnostics Centers
  • Others
  • Region Outlook (Revenue, USD Million, 2021-2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Market Definitions
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Product Snapshot
  • 2.3. Application and End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. Porter's Five Forces Analysis
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Breast Cancer Diagnostics Market: Type Movement Analysis, 2025 & 2033
  • 4.2. Imaging
    • 4.2.1. Imaging Market, 2021 - 2033 (USD Million)
  • 4.3. Biopsy
    • 4.3.1. Biopsy Market, 2021 - 2033 (USD Million)
  • 4.4. Genomic Tests
    • 4.4.1. Genomic Tests Market, 2021 - 2033 (USD Million)
  • 4.5. Blood Tests
    • 4.5.1. Blood Tests Market, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Product Business Analysis

  • 5.1. Breast Cancer Diagnostics Market: Product Movement Analysis, 2025 & 2033
  • 5.2. Platform-based products
    • 5.2.1. Platform-based Products Market, 2021 - 2033 (USD Million)
  • 5.3. Instrument-based products
    • 5.3.1. Instrument-based Products Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

  • 6.1. Breast Cancer Diagnostics Market: Application Movement Analysis, 2025 & 2033
  • 6.2. Screening
    • 6.2.1. Screening Market, 2021 - 2033 (USD Million)
  • 6.3. Diagnostic & Predictive
    • 6.3.1. Diagnostic & Predictive Market, 2021 - 2033 (USD Million)
  • 6.4. Prognostic
    • 6.4.1. Prognostic Market, 2021 - 2033 (USD Million)
  • 6.5. Research
    • 6.5.1. Research Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Breast Cancer Diagnostics Market: End Use Movement Analysis, 2025 & 2033
  • 7.2. Hospitals & Clinics
    • 7.2.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
  • 7.3. Medical labs & Diagnostics Centers
    • 7.3.1. Medical labs & Diagnostics Centers Market, 2021 - 2033 (USD Million)
  • 7.4. Others
    • 7.4.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Competitive Scenario
    • 8.2.3. Canada
      • 8.2.3.1. Canada Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Competitive Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.4.2. Key Country Dynamics
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Germany Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Competitive Scenario
    • 8.3.3. UK
      • 8.3.3.1. UK Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Competitive Scenario
    • 8.3.4. France
      • 8.3.4.1. France Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Competitive Scenario
    • 8.3.5. Italy
      • 8.3.5.1. Italy Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Competitive Scenario
    • 8.3.6. Spain
      • 8.3.6.1. Spain Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Competitive Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Competitive Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Competitive Scenario
    • 8.3.9. Norway
      • 8.3.9.1. Norway Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Competitive Scenario
    • 8.4.3. China
      • 8.4.3.1. China Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Competitive Scenario
    • 8.4.4. India
      • 8.4.4.1. India Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Competitive Scenario
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Competitive Scenario
    • 8.4.6. Australia
      • 8.4.6.1. Australia Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Competitive Scenario
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.2. Key Country Dynamics
    • 8.5.3. Regulatory Framework
    • 8.5.4. Competitive Scenario
    • 8.5.5. Brazil
      • 8.5.5.1. Brazil Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.5.2. Key Country Dynamics
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Competitive Scenario
    • 8.5.6. Argentina
      • 8.5.6.1. Argentina Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.6.2. Key Country Dynamics
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Competitive Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Competitive Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. Acquisition
    • 9.2.2. Collaborations
    • 9.2.3. New Platform Launches
    • 9.2.4. Others
  • 9.3. Company Profiles/Listing
    • 9.3.1. Hologic Inc.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Platform Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Genomic Health (Exact Sciences Corporation)
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Platform Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. BD
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Platform Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Danaher
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Platform Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Koninklijke Philips N.V
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Platform Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. QIAGEN
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Platform Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Thermo Fisher Scientific Inc
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Platform Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Myriad Genetics
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Platform Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Argon Medical Devices, Inc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Platform Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. F. Hoffmann-La Roche Ltd.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Platform Benchmarking
      • 9.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 4 Global Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 5 Global Breast Cancer Diagnostics Market, by Application, 2021 - 2033 (USD Million)
  • Table 6 Global Breast Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Million)
  • Table 7 Global Breast Cancer Diagnostics Market, by Region, 2021 - 2033 (USD Million)
  • Table 8 North America Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 9 North America Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 10 North America Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 11 North America Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 12 North America OTC U.S. Breast Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Million)
  • Table 13 U.S. Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 14 U.S. Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 15 U.S. Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 16 U.S. Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 17 Canada Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 18 Canada Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 19 Canada Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 20 Canada Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 21 Mexico Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 22 Mexico Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 23 Mexico Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 24 Mexico Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 25 Europe Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 26 Europe Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 27 Europe Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 28 Europe Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 29 Europe Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 30 UK Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 31 UK Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 32 UK Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 33 UK Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 34 Germany Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 35 Germany Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 36 Germany Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 37 Germany Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 38 France Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 39 France Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 40 France Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 41 France Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 42 Italy Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 43 Italy Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 44 Italy Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 45 Italy Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 46 Spain Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 47 Spain Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 48 Spain Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 49 Spain Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 50 Norway Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 51 Norway Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 52 Norway Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 53 Norway Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 54 Sweden Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 55 Sweden Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 56 Sweden Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 57 Sweden Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 58 Denmark Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 59 Denmark Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 60 Denmark Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 61 Denmark Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 67 Japan Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 68 Japan Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 69 Japan Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 70 Japan Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 71 China Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 72 China Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 73 China Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 74 China Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 75 India Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 76 India Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 77 India Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 78 India Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 79 Australia Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 80 Australia Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 81 Australia Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 82 Australia Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 83 South Korea Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 84 South Korea Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 85 South Korea Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 86 South Korea Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 87 Thailand Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 88 Thailand Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 89 Thailand Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 90 Thailand Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 91 Latin America Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 92 Latin America Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 93 Latin America Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 94 Latin America Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 95 Latin America Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 96 Brazil Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 97 Brazil Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 98 Brazil Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 99 Brazil Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 100 Argentina Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 101 Argentina Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 102 Argentina Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 103 Argentina Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 104 Middle East Africa Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 105 Middle East Africa Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 106 Middle East Africa Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 107 Middle East Africa Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 108 Middle East Africa Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 109 South Africa Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 110 South Africa Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 111 South Africa Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 112 South Africa Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 117 UAE Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 118 UAE Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 119 UAE Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 120 UAE Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 124 Kuwait Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)

List of Figures

  • FIG. 1 Market Research Process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary Research Pattern
  • FIG. 4 Market Research Approaches
  • FIG. 5 Value Chain-Based Sizing & Forecasting
  • FIG. 6 Market Formulation & Validation
  • FIG. 7 Market Segmentation
  • FIG. 8 Market Snapshot, 2025
  • FIG. 9 Market Trends & Outlook
  • FIG. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • FIG. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 Market Penetration & Growth Prospect Mapping, 2025
  • FIG. 15 Global Breast Cancer Diagnostics Market: Type Movement Analysis
  • FIG. 16 Global Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 17 Global Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 18 Global Genomic Tests Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 19 Global Blood Tests Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 20 Global Other Tests Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 21 Global Breast Cancer Diagnostics Market: Product Movement Analysis
  • FIG. 22 Global Platform-Based Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 23 Global Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 24 Global Biopsy Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 25 Global Instrument-Based Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 26 Global Microarrays Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 27 Global PCR Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 28 Global Next Generation Sequencing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 29 Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 30 Global Breast Cancer Diagnostics Market: Application Movement Analysis
  • FIG. 31 Global Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 32 Global Diagnostic & Predictive Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 33 Global Prognostic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 34 Global Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 35 Global Breast Cancer Diagnostics Market: End-Use Movement Analysis
  • FIG. 36 Global Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 37 Global Medical Labs & Diagnostics Centres Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 38 Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 39 Regional Marketplace: Key Takeaways
  • FIG. 40 Regional Outlook, 2025 & 2033
  • FIG. 41 Global Breast Cancer Diagnostics Market: Regional Movement Analysis
  • FIG. 42 North America Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 43 U.S. Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 44 Canada Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 45 Mexico Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 46 Europe Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 47 Germany Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 48 UK Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 49 France Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 50 Italy Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 51 Spain Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 52 Denmark Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 53 Sweden Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 54 Norway Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 55 Asia Pacific Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 56 Japan Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 57 China Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 58 India Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 59 Australia Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 60 South Korea Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 61 Thailand Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 62 Latin America Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 63 Brazil Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 64 Argentina Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 65 Middle East And Africa Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 66 South Africa Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 67 Saudi Arabia Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 68 UAE Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 69 Kuwait Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)